Group 1 - The core viewpoint of the article highlights the stability and growth of the medical insurance fund in 2024, with a total balance reaching 5.31 trillion yuan, indicating a smooth overall operation [1] - The number of participants in basic medical insurance remains stable at over 95%, with total income and expenditure both showing year-on-year growth [1] - Employee medical insurance shows a positive growth trend, with income increasing by 3.5% and expenditure by 7.6%, resulting in a current balance of 412 billion yuan [1] Group 2 - The National Tai Investment ETF tracks the SHS Innovation Drug Index, which reflects the overall performance of listed companies engaged in innovative drug research and production [1] - The index focuses on biopharmaceutical companies with core R&D capabilities and high growth potential, covering sub-sectors such as biopharmaceuticals and chemical pharmaceuticals [1] - Investors without stock accounts can consider the Guotai Zhongzheng Hong Kong and Shenzhen Innovation Drug Industry ETFs [1]